To our knowledge, this study is the first analysis of Caucasian ROS1-rearranged patients demonstrating an OS advantage compared to other patients with NSCLC, even when compared to targeted-treated EGFR-mutated and/or ALK-rearranged patients. The gene discussed is ALK; the disease is non-small cell lung carcinoma.